Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease

American Journal of Gastroenterology

Volumn 103, Issue 4, 2008, Pages 937-943

  Sternthal, Michael B ^a   Murphy, Seamus J ^a   George, James ^a   Kornbluth, Asher ^a   Lichtiger, Simon ^a   Present, Daniel H ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; COTRIMOXAZOLE; CYCLOSPORIN A; DILTIAZEM; MAGNESIUM SULFATE; NIFEDIPINE; VERAPAMIL;

ABSCESS; ADOLESCENT; ADULT; AGED; ANAPHYLAXIS; ANTIBIOTIC THERAPY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BACTERIAL PNEUMONIA; CATHETER INFECTION; CELLULITIS; COLITIS; COLORECTAL CANCER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROHN DISEASE; DRUG FATALITY; DRUG WITHDRAWAL; ENTERITIS; GINGIVA DISEASE; HEADACHE; HERPES SIMPLEX; HERPES SIMPLEX KERATITIS; HERPES ZOSTER; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPOMAGNESEMIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; NEPHROTOXICITY; OTITIS MEDIA; PARESTHESIA; PHLEBITIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEIZURE; SEPSIS; TREATMENT DURATION; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 41849130631     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01718.x     Document Type: Article

References (32)

1. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994 330 : 1841 5.
2. Kornbluth A, Lichtiger S, Present DH, et al. Long-term results of oral cyclosporine in patients with severe ulcerative colitis: A double-blind randomised, multi-center trial. Gastroenterology 1994 106 : A714.
3. Brynskov J, Freund L, Norby Rasmussen S, et al. Final report on a placebo-controlled, double-blind, randomized, multicentre trial of cyclosporin treatment in active chronic Crohn's disease. Scand J Gastroenterol 1991 26 : 689 95.
4. Egan LJ, Sandborn WJ, Tremaine WJ. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine. Am J Gastroenterol 1998 93 : 442 8.
5. Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn's disease. Dig Dis Sci 1994 39 : 374 80.
6. Feagan BG, McDonald JW, Rochon J, et al. Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial investigators. N Engl J Med 1994 330 : 1846 51.
7. Jewell DP, Lennard-Jones JE, Lowes J, et al. Oral cyclosporin for chronic active Crohn's disease: A multi-centre controlled trial. Eur J Gastroenterol Hepatol 1994 6 : 499 505.
8. Stange EF, Modigliani R, Pena AS, et al. European trial of cyclosporine in chronic active Crohn's disease: A 12-month study. The European Study Group. Gastroenterology 1995 109 : 774 82.
9. de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: Long-term consequences and challenges for the future. Am J Kidney Dis 2000 35 : 333 46.
10. Wijdicks EF, Wiesner RH, Krom RA. Neurotoxicity in liver transplant recipients with cyclosporine immunosuppression. Neurology 1995 45 : 1962 4.
11. Arts J, D'Haens G, Zeegers M, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004 10 : 73 8.
12. Campbell S, Travis S, Jewell D. Ciclosporin use in acute ulcerative colitis: A long-term experience. Eur J Gastroenterol Hepatol 2005 17 : 79 84.
13. Moskovitz DN, Van Assche G, Maenhout B, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006 4 : 760 5.
14. Kornbluth A, Present DH, Lichtiger S, et al. Cyclosporin for severe ulcerative colitis: A user's guide. Am J Gastroenterol 1997 92 : 1424 8.
15. Agrawal A, Durrani S, Leiper K, et al. Effect of systemic corticosteroid therapy on risk for intra-abdominal or pelvic abscess in non-operated Crohn's disease. Clin Gastroenterol Hepatol 2005 3 : 1215 20.
16. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: A five-year experience. Am J Gastroenterol 1999 94 : 1587 92.
17. Kozarek R, Bedard C, Patterson D, et al. Cyclosporin use in the precolectomy chronic ulcerative colitis patient: A community experience and its relationship to prospective and controlled clinical trials. Pacific Northwest Gastroenterology Society. Am J Gastroenterol 1995 90 : 2093 6.
18. Marion JF, Present DH. 6-MP maintains cyclosporine induced response in patients with ulcerative colitis. Am J Gastroenterol 1996 94 : A356.
19. Assan R, Timsit J, Feutren G, et al. The kidney in cyclosporin A-treated diabetic patients: A long-term clinicopathological study. Clin Nephrol 1994 41 : 41 9.
20. Mahadevan U, Kornbluth A, Goldstein E, et al. Cyclosporine induced nephrotoxicity: Permanent or progressive in patients with inflammatory bowel disease? Gastroenterology 1997 117 : A1030.
21. Porayko MK, Textor SC, Krom RA, et al. Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation. Mayo Clin Proc 1994 69 : 105 11.
22. Palestine AG, Nussenblatt RB, Chan CC. Side effects of systemic cyclosporine in patients not undergoing transplantation. Am J Med 1984 77 : 652 6.
23. Feutren G, Querin S, Noel LH, et al. Effects of cyclosporine in severe systemic lupus erythematosus. J Pediatr 1987 111 : 1063 8.
24. Feutren G, Mihatsch MJ. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. N Engl J Med 1992 326 : 1654 60.
25. Dawidson I, Rooth P, Fry WR, et al. Prevention of acute cyclosporine-induced renal blood flow inhibition and improved immunosuppression with verapamil. Transplantation 1989 48 : 575 80.
26. Rossi SJ, Schroeder TJ, Hariharan S, et al. Prevention and management of the adverse effects associated with immunosuppressive therapy. Drug Saf 1993 9 : 104 31.
27. Bernstein CN, Kolodny M, Block E, et al. Pneumocystis carinii pneumonia in patients with ulcerative colitis treated with corticosteroids. Am J Gastroenterol 1993 88 : 574 7.
28. Arellano F, Krupp P. Malignancies in rheumatoid arthritis patients treated with cyclosporin A. Br J Rheumatol 1993 32 (Suppl 1) : 72 5.
29. Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: A randomized, placebo-controlled trial. Gastroenterology 2003 125 : 380 8.
30. Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006 55 : 1255 62.
31. Colombel JF, Loftus EV Jr., Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients. Gastroenterology 2004 126 : 19 31.
32. Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: Clinical outcome in a population based cohort from Stockholm County. Gut 2004 53 : 849 53.